Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Clonazepam

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,085Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Enforcement Report - Week of January 15, 2025
    Enforcement Report - Week of January 15, 2025

    15 Jan 2025

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-15-2025-7287.pdf

    FDA
    15 Jan 2025
    Share Share
    Endo Expands Voluntary Recall of Clonazepam Orally Tablets
    Endo Expands Voluntary Recall of Clonazepam Orally Tablets

    19 Nov 2024

    // FDA

    https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/endo-expands-voluntary-recall-clonazepam-orally-disintegrating-tablets-usp-c-iv-due-potential

    FDA
    19 Nov 2024
    Share Share
    Endo Expands Voluntary Recall of Clonazepam Due to Mislabeling
    Endo Expands Voluntary Recall of Clonazepam Due to Mislabeling

    18 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/endo-expands-voluntary-recall-of-clonazepam-orally-disintegrating-tablets-usp-c-iv-due-to-potential-product-carton-strength-mislabeling-302309074.html

    PR NEWSWIRE
    18 Nov 2024
    Share Share
    Enforcement Report for Week of August 7, 2024
    Enforcement Report for Week of August 7, 2024

    07 Aug 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-for-week-of-august-7-2024-64880.pdf

    FDA
    07 Aug 2024
    Share Share
    Endo Issues Voluntary Nationwide Recall of Clonazepam Tablets
    Endo Issues Voluntary Nationwide Recall of Clonazepam Tablets

    17 Jul 2024

    // FDA

    https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/endo-usa-inc-issues-voluntary-nationwide-recall-one-lot-clonazepam-orally-disintegrating-tablets-usp

    FDA
    17 Jul 2024
    Share Share
    Endo USA Recalls Mislabeled Clonazepam Tablets Lot 550147301
    Endo USA Recalls Mislabeled Clonazepam Tablets Lot 550147301

    16 Jul 2024

    // PRESS RELEASE

    https://investor.endo.com/2024-07-16-Endo-USA,-Inc-Issues-Voluntary,-Nationwide-Recall-of-One-Lot-of-Clonazepam-Orally-Disintegrating-Tablets,-USP-C-IV-Lot-Number-550147301-Due-to-Mislabeling-Incorrect-Strength-on-Product-Carton

    PRESS RELEASE
    16 Jul 2024
    Share Share